Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Completed · Phase 3

Conditions studied: Moderate to Severe Chronic Plaque-type Psoriasis

In brief

The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.

Key facts

Study ID
NCT03504852
Run by
Novartis Pharmaceuticals
People needed
331
Starts
2018-06-25
Expected to finish
2020-07-15
Last updated by the study team
2021-10-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.